SEARCH:   Advanced

Blood, Vol. 112, Issue 5, 1960-1970, September 1, 2008 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef Absence of SKP2 expression attenuates BCR-ABL–induced myeloproliferative disease Blood Agarwal et al. 112: 1960 Supplemental materials for: Agarwal et al Files in this Data Supplement: Figure S1. Mo7e cells expressing p210BCR-ABL were treated with 2.5 µM imatinib for the indicated times (JPG, 94.9 KB) - (A) Cell cycle profiles determined by PI staining. (B) Expression of p27 in nuclear (N) and cytoplasmic (C) fractions. Actin was used as a loading control. Figure S2. Effect of compound 3 (C14H11 BrN4 O3S), a specific CDK2 inhibitor on CDK activity (JPG, 57.1 KB) - Figure S3. Inhibition of BCR-ABL kinase activity is associated with downregulation of SKP2 and upregulation of p27 in BCR-ABL-positive cell lines (JPG, 117 KB) - p27 and SKP2 expression were measured in whole cell lysates of cells treated with 2.5 µM imatinib for 16 hrs. (A) Mo7ep210BCR-ABL; (B) Ba/F3p210BCR-ABL and 32Dp210BCR-ABL; (C) K562, KYO-1 cells (left panel). The cell cycle profile was analyzed by PI staining for K562 and KYO-1 cells (right panel). Figure S4. Flow cytometric analysis of bone marrow and spleen cells from recipient mice transplanted with SKP2+/+ and SKP2−/− marrow transduced with p210BCR-ABL (JPG, 107 KB) - Each surface marker represents the percentage of positive cell within the GFP-positive population. (A,C) bone marrow, (B, D) spleen. Significant differences at p<0.05 are indicated by an asterisk. This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020